Maynard Um
-
-
-
-
-
-
-
Vaxcyte, Inc. (PCVX) Misses Q4 EPS by $4.13
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Vaxcyte, Inc. (PCVX) Reports In-Line Q1 EPS
-
-
-
-
-
-
-
Mizuho Reiterates Outperform Rating on Vaxcyte (PCVX), PT $163
-
-
-
-
-
-
-
Vaxcyte (PCVX) PT Raised to $146 at Jefferies
-
-
-
-
-
-
-
Vaxcyte, Inc (PCVX) Prices $1.3B Share Offering at $103/sh
-
-
-
-
-
-
-
Vaxcyte (PCVX) PT Raised to $129 at Jefferies
-
431,601 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

